UroGen Pharma Ltd. (URGN)
UroGen Pharma Statistics
Share Statistics
UroGen Pharma has 46.09M shares outstanding. The number of shares has increased by 12.07% in one year.
| Shares Outstanding | 46.09M |
| Shares Change (YoY) | 12.07% |
| Shares Change (QoQ) | 9.23% |
| Owned by Institutions (%) | 84.16% |
| Shares Floating | 38.22M |
| Failed to Deliver (FTD) Shares | 26 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 5.99M, so 14.2% of the outstanding shares have been sold short.
| Short Interest | 5.99M |
| Short % of Shares Out | 14.2% |
| Short % of Float | 16.4% |
| Short Ratio (days to cover) | 12.4 |
Valuation Ratios
The PE ratio is -3.6 and the forward PE ratio is -3.98. UroGen Pharma's PEG ratio is 0.22.
| PE Ratio | -3.6 |
| Forward PE | -3.98 |
| PS Ratio | 5.05 |
| Forward PS | 0.5 |
| PB Ratio | -51.87 |
| P/FCF Ratio | -4.7 |
| PEG Ratio | 0.22 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for UroGen Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.01, with a Debt / Equity ratio of -14.02.
| Current Ratio | 6.01 |
| Quick Ratio | 5.81 |
| Debt / Equity | -14.02 |
| Debt / EBITDA | -1.12 |
| Debt / FCF | -1.27 |
| Interest Coverage | -7.73 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $384.67K |
| Profits Per Employee | $-539.89K |
| Employee Count | 235 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 0.96 |
Taxes
| Income Tax | 2.83M |
| Effective Tax Rate | -2.28% |
Stock Price Statistics
The stock price has increased by -22.24% in the last 52 weeks. The beta is 0.81, so UroGen Pharma's price volatility has been higher than the market average.
| Beta | 0.81 |
| 52-Week Price Change | -22.24% |
| 50-Day Moving Average | 10.67 |
| 200-Day Moving Average | 12.57 |
| Relative Strength Index (RSI) | 42.25 |
| Average Volume (20 Days) | 390.61K |
Income Statement
In the last 12 months, UroGen Pharma had revenue of 90.4M and earned -126.87M in profits. Earnings per share was -2.96.
| Revenue | 90.4M |
| Gross Profit | 81.52M |
| Operating Income | -96.78M |
| Net Income | -126.87M |
| EBITDA | -110.33M |
| EBIT | -111.52M |
| Earnings Per Share (EPS) | -2.96 |
Balance Sheet
The company has 171.99M in cash and 123.39M in debt, giving a net cash position of 48.6M.
| Cash & Cash Equivalents | 171.99M |
| Total Debt | 123.39M |
| Net Cash | 48.6M |
| Retained Earnings | -806.22M |
| Total Assets | 285.71M |
| Working Capital | 230.19M |
Cash Flow
In the last 12 months, operating cash flow was -96.77M and capital expenditures -295K, giving a free cash flow of -97.06M.
| Operating Cash Flow | -96.77M |
| Capital Expenditures | -295K |
| Free Cash Flow | -97.06M |
| FCF Per Share | -2.26 |
Margins
Gross margin is 90.18%, with operating and profit margins of -107.06% and -140.35%.
| Gross Margin | 90.18% |
| Operating Margin | -107.06% |
| Pretax Margin | -137.22% |
| Profit Margin | -140.35% |
| EBITDA Margin | -122.05% |
| EBIT Margin | -107.06% |
| FCF Margin | -107.37% |
Dividends & Yields
URGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for URGN is $35.5, which is 252.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $35.5 |
| Price Target Difference | 252.5% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -2.86 |
| Piotroski F-Score | 2 |